Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
Peled N, Roisman LC, Levison E, Dudnik J, Chernomordikov E, Heching N, Dudnik E, Keren-Rosenberg S, Nechushtan H, Salhab A, Hershkovitz D, Tsuriel S, Hannes V, Rotem O, Lazarev I, Lichtenberg R, Granot IS, Krayim B, Shalata W, Levin D, Krutman Y, Allen AM, Blumenfeld P, Lavrenkov K, Kian W. Peled N, et al. Among authors: heching n. Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):105-114. doi: 10.1016/j.ijrobp.2023.03.042. Epub 2023 Mar 15. Int J Radiat Oncol Biol Phys. 2023. PMID: 36925073 Clinical Trial.
Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, Barak V. Nisman B, et al. Among authors: heching n. Cancer. 1998 May 15;82(10):1850-9. doi: 10.1002/(sici)1097-0142(19980515)82:10<1850::aid-cncr6>3.0.co;2-r. Cancer. 1998. PMID: 9587116 Clinical Trial.
Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival.
Nisman B, Biran H, Heching N, Barak V, Ramu N, Nemirovsky I, Peretz T. Nisman B, et al. Among authors: heching n. Br J Cancer. 2008 Jan 15;98(1):77-9. doi: 10.1038/sj.bjc.6604157. Epub 2007 Dec 18. Br J Cancer. 2008. PMID: 18087272 Free PMC article.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Intravascular Small Cell Carcinoma Disguised as Pulmonary Embolism.
Rokach A, Hochberg-Klein S, Arish N, Doviner V, Bar-Shalom R, Turner Y, Heching N, Heyman SN. Rokach A, et al. Among authors: heching n. Isr Med Assoc J. 2021 Jan;23(1):52-54. Isr Med Assoc J. 2021. PMID: 33443344 Free article. No abstract available.
20 results